



June 2015
Volume 56, Issue 7

ISSUE

Jump To...
Abstract

FREE

ARVO Annual Meeting Abstract | June 2015

Trans-epithelial cross-linking for treatment of progressive keratoconus in eyes with thin cornea

Antonio Longo; Michele Reibaldi; Maurizio G Uva; Caterina Gagliano; Francesco Occhipinti; Michele Bellino; Vincenza Bonfiglio; Mario Damiano Toro; Matteo Fallico; Teresio Avitabile

+ Author Affiliations & Notes

Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5822. doi:<https://doi.org/>

SHARE

TOOLS

Abstract

Purpose

To evaluate the visual, refractive and corneal tomographic effects of trans-epithelial cross-linking (TE-CXL) in patients with progressive keratoconus (KC) and thin cornea.

Methods

Were included in this study all consecutive patients affected with progressive KC and thin cornea (thinnest < 400 microns) that have been treated with TE-CXL. Visual acuity, refraction, corneal tomographic parameters as assessed by Orbscan II, and endothelial cells density (ECD), at baseline and at last visit (minimum follow up: 2 years) were compared. KC progression was considered an increase in mean K of at least 1.5 D

Results

Were treated with TE-CXL 33 eyes of 33 patients (age 22-31 years). At baseline mean corrected distance visual acuity (CDVA) was 0.22 ± 0.11 logMAR; SimK max was 53.3 ± 3.7 D, and SimK min was 48.2 ± 2.2 D. Eight eyes had stage I KC, 15 a stage II KC, 10 a stage III KC. Mean corneal thickness at thinnest point was 380 ± 20 microns. After a mean follow-up of 31 ± 4 months (range 25-38), a KC stabilization (with CDVA increase) was detected in 28 eyes, while a KC progression (with unchanged CDVA) was seen in 5 eyes, that were retreated. Eyes with KC progression had a greater baseline SimK Astigmatism (7.2 ± 1.9 D vs 4.8 ± 2.5 D, $p=0.046$) than eyes without KC progression. A 4.1% reduction in mean ECD was detected (from 2946 ± 239 cells/mm² to 2829 ± 292 cells/mm²).

Conclusions

TE-CXL stabilizes keratoconus in most of eyes with thin cornea (thinnest <400 microns), for which standard CXL is contraindicated, with a limited corneal endothelium damage.

193

Views

0

Citations

View Metrics

Advertisement

ARVO Learn offers education opportunities to vision researchers worldwide, with 24-7 access. Member and nonmember options available.

Highlights of ARVO Learn

- ARVO/AAA collaborative webinars
- Learning modules and courses on a variety of eye and vision research topics
- Session recordings from recent ARVO meetings and conferences

ARVOLearn.org